Localized Discoid Lupus Erythematosus: What to Do After Retinoid Therapy Failure

This protocol covers the management of localized skin lesions of discoid lupus erythematosus in patients without severe or widespread skin involvement, without risk of scarring or progression to systemic disease, and who are not pregnant or breastfeeding.

Prior Treatment Line — Response Not Achieved

The preceding regimen included retinoids (acitretin or isotretinoin) in addition to antimalarials, or dapsone in addition to antimalarials. This next-line protocol applies when response to retinoid therapy is not achieved within 2 to 6 weeks of treatment.

Next-Line Approach

When localized DLE does not respond to the retinoid-based regimen, the protocol escalates to a mycophenolate-based agent used in combination with antimalarials. The complete regimen — including agent selection, titration approach, and monitoring guidance — is available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes.
We recommend MMF as third-line treatment in refractory CLE patients, preferably in addition to antimalarials.
We recommend 2 x 500 mg MMF per day as starting dose that can be increased up to 3 g per day depending on the clinical response.
We suggest MPA as an alternative treatment to MMF.

View source ↗